Advancing Relapsed and Refractory Multiple Myeloma (RRMM) Care Through Communities of Practice

Multiple myeloma remains an incurable disease, with high relapse rates and a disproportionate impact on patients with African ancestry. New B-cell maturation antigen (BCMA) bispecific antibodies (bsAbs) show promise, but many clinicians report gaps in guideline familiarity, adverse event management, and access to coordinated care.

Register today for the Multiple Myeloma Community of Practice ECHO^® program to:

• Join a multidisciplinary team of expert faculty for interactive Project ECHO^® sessions and live Q&A Community of Practice discussions
• Access clinician and patient toolkits, along with other resources, to support you in delivering high-quality care
• Learn best practices for implementing the use of BCMA bsAbs

Play the video to hear Ajay K. Nooka, MD, and Raphael E. Szalat, MD, PhD, introduce the MM Project ECHO program and learn why it is critical for community oncology teams to be familiar with the administration of BCMA-directed bsAbs and the importance of implementing bsAbs in their practice.